WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407427
Description: OXA-01 is an inhibitor of both mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively). OXA-01 targeted both mTORC1 and mTORC2 signaling in vitro and in vivo. OXA-01 reduced VEGF production in tumors in a manner associated with decreased vessel sprouting but little vascular regression.
MedKoo Cat#: 407427
Chemical Formula: C21H20ClN5O2
Exact Mass: 409.1306
Molecular Weight: 409.874
Elemental Analysis: C, 61.54; H, 4.92; Cl, 8.65; N, 17.09; O, 7.81
Synonym: OXA-01; OXA01; OXA 01.
IUPAC/Chemical Name: trans-4-[8-amino-1-(7-chloro-1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid
InChi Key: UXCAKZGNKOZXBM-HAQNSBGRSA-N
InChi Code: InChI=1S/C21H20ClN5O2/c22-14-3-1-2-13-10-15(25-16(13)14)17-18-19(23)24-8-9-27(18)20(26-17)11-4-6-12(7-5-11)21(28)29/h1-3,8-12,25H,4-7H2,(H2,23,24)(H,28,29)/t11-,12-
SMILES Code: O=C([C@H]1CC[C@H](C2=NC(C(N3)=CC4=C3C(Cl)=CC=C4)=C5C(N)=NC=CN52)CC1)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 409.874 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman
J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ,
Pachter JA. Preclinical characterization of OSI-027, a potent and selective
inhibitor of mTORC1 and mTORC2: distinct from rapamycin. Mol Cancer Ther. 2011
Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. PubMed PMID: 21673091.
2: Falcon BL, Barr S, Gokhale PC, Chou J, Fogarty J, Depeille P, Miglarese M,
Epstein DM, McDonald DM. Reduced VEGF production, angiogenesis, and vascular
regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors.
Cancer Res. 2011 Mar 1;71(5):1573-83. doi: 10.1158/0008-5472.CAN-10-3126. PubMed
PMID: 21363918; PubMed Central PMCID: PMC3077087.